Gensight Biologics SA - Asset Resilience Ratio

Latest as of June 2022: 59.58%

Gensight Biologics SA (SIGHT) has an Asset Resilience Ratio of 59.58% as of June 2022. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

€24.15 Million

≈ $28.23 Million USD Cash + Short-term Investments

Total Assets

€40.52 Million

≈ $47.38 Million USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2014–2021)

This chart shows how Gensight Biologics SA's Asset Resilience Ratio has changed over time. Check Gensight Biologics SA (SIGHT) strategic asset index to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Gensight Biologics SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Gensight Biologics SA worth.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€24.15 Million	59.58%
Short-term Investments	€0.00	0%
Total Liquid Assets	€24.15 Million	59.58%

Asset Resilience Insights

Very High Liquidity: Gensight Biologics SA maintains exceptional liquid asset reserves at 59.58% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Gensight Biologics SA Industry Peers by Asset Resilience Ratio

Compare Gensight Biologics SA's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Shanghai Allist Pharmaceuticals Co. Ltd. A SHG:688578	Biotechnology	21.11%
Tubize-Fin BR:TUB	Biotechnology	0.05%
Sk Biopharmaceuticals Co Ltd KO:326030	Biotechnology	0.14%
Tango Therapeutics Inc NASDAQ:TNGX	Biotechnology	57.90%
TELIX Pharmaceuticals Ltd AU:TLX	Biotechnology	32.29%
Xiamen Amoytop Biotech Co Ltd SHG:688278	Biotechnology	4.69%
Hangzhou Biotest Biotech Co Ltd SHG:688767	Biotechnology	0.56%
Theravance Biopharma Inc F:0TB	Biotechnology	37.29%

Annual Asset Resilience Ratio for Gensight Biologics SA (2014–2021)

The table below shows the annual Asset Resilience Ratio data for Gensight Biologics SA.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2021-12-31	78.18%	€44.29 Million ≈ $51.78 Million	€56.65 Million ≈ $66.23 Million	-1.93pp
2020-12-31	80.11%	€37.94 Million ≈ $44.36 Million	€47.36 Million ≈ $55.37 Million	+20.85pp
2019-12-31	59.26%	€19.25 Million ≈ $22.51 Million	€32.48 Million ≈ $37.98 Million	-11.70pp
2018-12-31	70.96%	€26.24 Million ≈ $30.68 Million	€36.98 Million ≈ $43.23 Million	-18.17pp
2017-12-31	89.13%	€55.45 Million ≈ $64.82 Million	€62.21 Million ≈ $72.73 Million	-2.01pp
2016-12-31	91.14%	€53.98 Million ≈ $63.11 Million	€59.23 Million ≈ $69.25 Million	+81.68pp
2014-12-31	9.46%	€1.40 Million ≈ $1.64 Million	€14.82 Million ≈ $17.32 Million	--

pp = percentage points

About Gensight Biologics SA

PA:SIGHT France Biotechnology

Market Cap

$23.57 Million

€20.16 Million EUR

Market Cap Rank

#25193 Global

#412 in France

Share Price

€0.09

Change (1 day)

+2.38%

52-Week Range

€0.08 - €0.17

All Time High

€9.58